Skip to main content
. 2017 Sep 22;61(10):e00875-17. doi: 10.1128/AAC.00875-17

FIG 1.

FIG 1

MIC distribution (%) for ceftazidime-avibactam and ceftolozane-tazobactam of 290 meropenem-nonsusceptible blood, respiratory, and wound P. aeruginosa isolates. The susceptibility breakpoints for ceftazidime-avibactam and ceftolozane-tazobactam are 8 mg/liter (*) and 4 mg/liter (#), respectively.